ATE353318T1 - Neue indolderivate mit affinität zum 5-ht6- rezeptor - Google Patents

Neue indolderivate mit affinität zum 5-ht6- rezeptor

Info

Publication number
ATE353318T1
ATE353318T1 AT02735394T AT02735394T ATE353318T1 AT E353318 T1 ATE353318 T1 AT E353318T1 AT 02735394 T AT02735394 T AT 02735394T AT 02735394 T AT02735394 T AT 02735394T AT E353318 T1 ATE353318 T1 AT E353318T1
Authority
AT
Austria
Prior art keywords
affinity
receptor
indole derivatives
new indole
new
Prior art date
Application number
AT02735394T
Other languages
English (en)
Inventor
Colin Charles Beard
Robin Douglas Clark
Lawrence Emerson Fisher
Ralph New Harris Iii
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE353318T1 publication Critical patent/ATE353318T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02735394T 2001-06-07 2002-05-29 Neue indolderivate mit affinität zum 5-ht6- rezeptor ATE353318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29670501P 2001-06-07 2001-06-07
US34021201P 2001-12-13 2001-12-13

Publications (1)

Publication Number Publication Date
ATE353318T1 true ATE353318T1 (de) 2007-02-15

Family

ID=26969776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02735394T ATE353318T1 (de) 2001-06-07 2002-05-29 Neue indolderivate mit affinität zum 5-ht6- rezeptor

Country Status (33)

Country Link
US (3) US6787535B2 (de)
EP (1) EP1401813B1 (de)
JP (1) JP4187642B2 (de)
KR (1) KR100600240B1 (de)
CN (1) CN1257892C (de)
AR (1) AR036233A1 (de)
AT (1) ATE353318T1 (de)
AU (1) AU2002310747B2 (de)
BG (1) BG108420A (de)
BR (1) BR0210929A (de)
CA (1) CA2449874C (de)
CO (1) CO5630036A2 (de)
CZ (1) CZ20033529A3 (de)
DE (1) DE60218037T2 (de)
ES (1) ES2280546T3 (de)
HK (1) HK1068610A1 (de)
HR (1) HRP20030984A2 (de)
HU (1) HUP0401307A2 (de)
IL (1) IL158997A0 (de)
MA (1) MA27032A1 (de)
MX (1) MXPA03011244A (de)
NO (1) NO20035359D0 (de)
NZ (1) NZ529631A (de)
PA (1) PA8546601A1 (de)
PE (1) PE20030039A1 (de)
PL (1) PL367305A1 (de)
RU (1) RU2294932C2 (de)
SK (1) SK16052003A3 (de)
TW (1) TW591015B (de)
UY (1) UY27322A1 (de)
WO (1) WO2002098857A1 (de)
YU (1) YU96103A (de)
ZA (1) ZA200309005B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144883B2 (en) 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
EP1414442A1 (de) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl-indole, -benzofurane und -benzothiophene mit 5-ht6-rezeptor-affinität für die behandlung von erkrankungen des zentralen nervensystems
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
EP1513828A1 (de) * 2002-06-20 2005-03-16 Biovitrum AB Neue, zur behandlung von obesitas, typ ii-diabetes und zns-erkrankungen geeignete verbindungen
EP1897881A3 (de) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
KR100686758B1 (ko) * 2002-09-17 2007-02-26 에프. 호프만-라 로슈 아게 2,7-치환된 인돌 및 5-ｈｔ6 조절 인자로서의 그 용도
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EA010298B1 (ru) * 2003-12-19 2008-08-29 Биовитрум Аб (Пабл) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
MXPA06007172A (es) 2003-12-23 2006-08-23 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-bencilamina como ssri.
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) * 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CA2582273C (en) * 2004-09-30 2013-10-29 Douglas William Bonhaus Compositions and methods for treating cognitive disorders using serotonin receptor antagonists
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101282938A (zh) * 2005-08-15 2008-10-08 惠氏公司 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物
ES2274725B1 (es) * 2005-11-08 2008-04-01 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
US7645752B2 (en) * 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
US7696229B2 (en) * 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
CA2668959A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
EP2114878B1 (de) 2007-01-08 2010-12-15 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indolverbindungen und ihre verwendung als 5-ht6-liganden
JP2010515673A (ja) * 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ４−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのその使用
WO2008101247A2 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
EP2120950B1 (de) * 2007-03-21 2012-07-04 Glaxo Group Limited Verwendung von chinolin-derivaten zur behandlung von schmerzen
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CA2683124C (en) 2007-05-03 2012-09-25 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
US20080318941A1 (en) * 2007-05-24 2008-12-25 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
KR20100053626A (ko) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 나타내는 3'-치환된 화합물
JP5236001B2 (ja) 2007-10-26 2013-07-17 スヴェン・ライフ・サイエンシズ・リミテッド アミノアリールスルホンアミド化合物および５−ｈｔ６リガンドとしてのその使用
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
BRPI0908807A2 (pt) * 2008-02-15 2015-07-28 Hoffmann La Roche Derivados de 3-alquil-piperazina e usos dos mesmos
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
EA019496B1 (ru) 2008-09-17 2014-04-30 Сувен Лайф Сайенсиз Лимитед Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
NZ601284A (en) 2010-01-05 2014-03-28 Suven Life Sciences Ltd Sulfone compounds as 5-ht6 receptor ligands
WO2012024620A2 (en) 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN102924359B (zh) * 2012-10-30 2015-03-11 中国科学院烟台海岸带研究所 一种一锅法合成取代吲哚类化合物的方法
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
BR9809092A (pt) * 1997-04-18 2002-01-22 Smithkline Beecham Plc Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE69937372T2 (de) * 1999-04-21 2008-06-26 Nps Allelix Corp., Mississauga Piperidin-indol derivate mit 5-ht6 affinität
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
KR100822655B1 (ko) * 2000-11-02 2008-04-17 와이어쓰 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CA2432654A1 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
BR0116481A (pt) * 2000-12-22 2004-01-06 Wyeth Corp Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP4323810B2 (ja) * 2001-04-20 2009-09-02 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルオキシ−、−チオキシ−および−アミノベンザゾール誘導体
EP1414442A1 (de) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl-indole, -benzofurane und -benzothiophene mit 5-ht6-rezeptor-affinität für die behandlung von erkrankungen des zentralen nervensystems
ES2274285T3 (es) * 2002-10-18 2007-05-16 F. Hoffmann-La Roche Ag 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6.

Also Published As

Publication number Publication date
US20030073700A1 (en) 2003-04-17
PE20030039A1 (es) 2003-02-13
JP2004533460A (ja) 2004-11-04
US20050171118A1 (en) 2005-08-04
US20040248902A1 (en) 2004-12-09
PL367305A1 (en) 2005-02-21
JP4187642B2 (ja) 2008-11-26
CN1527816A (zh) 2004-09-08
YU96103A (sh) 2006-08-17
CN1257892C (zh) 2006-05-31
BG108420A (en) 2005-02-28
PA8546601A1 (es) 2003-01-24
TW591015B (en) 2004-06-11
US6787535B2 (en) 2004-09-07
EP1401813A1 (de) 2004-03-31
HK1068610A1 (en) 2005-04-29
CA2449874C (en) 2009-06-23
KR20040004702A (ko) 2004-01-13
BR0210929A (pt) 2004-06-08
DE60218037T2 (de) 2007-08-23
SK16052003A3 (en) 2004-10-05
KR100600240B1 (ko) 2006-07-13
AR036233A1 (es) 2004-08-25
EP1401813B1 (de) 2007-02-07
NZ529631A (en) 2006-08-31
CZ20033529A3 (cs) 2004-04-14
MA27032A1 (fr) 2004-12-20
RU2003136731A (ru) 2005-05-20
IL158997A0 (en) 2004-05-12
CA2449874A1 (en) 2002-12-12
WO2002098857A8 (en) 2004-04-22
MXPA03011244A (es) 2004-02-27
DE60218037D1 (de) 2007-03-22
ZA200309005B (en) 2005-02-21
AU2002310747B2 (en) 2007-10-11
NO20035359D0 (no) 2003-12-02
CO5630036A2 (es) 2006-04-28
ES2280546T3 (es) 2007-09-16
HRP20030984A2 (en) 2005-10-31
WO2002098857A1 (en) 2002-12-12
HUP0401307A2 (hu) 2004-12-28
RU2294932C2 (ru) 2007-03-10
UY27322A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE353318T1 (de) Neue indolderivate mit affinität zum 5-ht6- rezeptor
DE60212841D1 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
DE60309498D1 (de) 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
ATE465995T1 (de) N-'(1,5-diphenyl-1h-pyrazol-3- yl)sulfonamidderivate mit affinität zum cb1- rezeptor
DE60328671D1 (de) Neue aminobenzamidderivate
ATE506360T1 (de) Neue benzimidazolderivate
DE50105334D1 (de) Neue carbamat-substituierte pyrazolopyridinderivate
DE60030035D1 (de) Mehrschichtige Struktur
ATE271031T1 (de) Neue phenylpropargyletherderivate
DE50307129D1 (de) Aza-bicyclische n-biarylamide mit affinität zum alpha7 nikotinischen acetylcholin-rezeptor
DE50202178D1 (de) Neue sulfonat-substituierte pyrazolopyridinderivate
ATE390430T1 (de) Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor
ATE298752T1 (de) Neue pyridin-substituierte pyrazolopyridinderivate
IS7754A (is) Prólín afleiður með sækni fyrir kalkganga alfa-2-delta undireininguna
DE50014679D1 (de) Substituierte indol-mannichbasen
DE50111292D1 (de) Neue sulfonamid-substituierte pyrazolopyridinderivate
ATE421506T1 (de) Neue benzimidazolderivate
DE60014662D1 (de) Verbesserungen in der schadstoffausstossregelung
DE60319184D1 (de) Dreirad mit Schwingmechanismus
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
NO20015737L (no) Indol derivater
ATE445604T1 (de) Neue 2,6-diaminopyridin-3-on-derivate
DE60111268D1 (de) Neue pleuromutilinderivate
DE60103033D1 (de) Neue phenylheteroalkylamin-derivate
ATE487694T1 (de) Neue phthalamidderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401813

Country of ref document: EP

REN Ceased due to non-payment of the annual fee